Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'

被引:747
作者
Drusano, GL [1 ]
机构
[1] Ordway Res Inst, Albany, NY 12208 USA
关键词
D O I
10.1038/nrmicro862
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学]; 100705 [微生物与生化药学];
摘要
Antimicrobial pharmacodynamics is the discipline that integrates microbiology and pharmacology, with the aim of linking a measure of drug exposure, relative to a measure of drug potency for the pathogen in question, to the microbiological or clinical effect achieved. The delineation of such relationships allows the drug dose to be chosen in a rational manner, so that the desired effect ( for example, the maximal bactericidal effect) can be achieved in a large proportion of the intended patient population. Ultimately, the goal of any anti-infective therapy is to administer a dose of drug that has an acceptably high probability of achieving the desired therapeutic effect balanced with an acceptably low probability of toxicity. Appropriate use of the latest pharmacodynamic modelling approaches can minimize the emergence of resistance and optimize the outcome for patients.
引用
收藏
页码:289 / 300
页数:12
相关论文
共 46 条
[1]
Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[2]
AMBROSE PG, 2002, 42 INT C ANT AG CHEM
[3]
Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models [J].
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1665-1670
[4]
Human serum alpha(1) acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease [J].
Bilello, JA ;
Bilello, PA ;
Stellrecht, K ;
Leonard, J ;
Norbeck, DW ;
Kempf, DJ ;
Robins, T ;
Drusano, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1491-1497
[5]
Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses [J].
Chien, SC ;
Rogge, MC ;
Gisclon, LG ;
Curtin, C ;
Wong, F ;
Natarajan, J ;
Williams, RR ;
Fowler, CL ;
Cheung, WK ;
Chow, AT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2256-2260
[6]
Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers [J].
Chow, AT ;
Fowler, C ;
Williams, RR ;
Morgan, N ;
Kaminski, S ;
Natarajan, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :2122-2125
[7]
Does the dose matter? [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 2001, 33 :S233-S237
[8]
Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[10]
PHARMACODYNAMICS OF AMIKACIN INVITRO AND IN MOUSE THIGH AND LUNG INFECTIONS [J].
CRAIG, WA ;
REDINGTON, J ;
EBERT, SC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :29-40